Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
2018
AbstractThe aim of this study was to understand current trends in trastuzumab use in China as a neoadjuvant/adjuvant therapy for human epidermal growth factor receptor-2 positive (HER2+) breast cancer and identify factors influencing trastuzumab use.This was a retrospective, multicenter, cross-secti
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
23
References
6
Citations
NaN
KQI